Abstract:Unhealthy lifestyle habits including a sedentary life, the lack of physical activity, and wrong dietary habits are the major ones responsible for the constant increase of obesity and metabolic disorders prevalence worldwide; therefore, the scientific community pays significant attention to the pharmacotherapy of such diseases, beyond lifestyle interventions, the use of medical devices, and surgical approaches. The intricate interplay between autophagy and inflammation appears crucial to orchestrate fundamental aspects of cellular and organismal responses to challenging stimuli, including metabolic insults; hence, when these two processes are dysregulated (enhanced or suppressed) they produce pathologic effects. The present review summarizes the existing literature reporting the intricate affair between autophagy and inflammation in the context of metabolic disorders, including obesity, diabetes, and liver metabolic diseases (non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)). The evidence collected so far suggests that an alteration of autophagy might lead to maladaptive metabolic and inflammatory responses thus exacerbating the severity of the disease, and the most prominent conclusion underlies that autophagy might exert a protective function by contributing to balance inflammation. However, the complex nature of obesity and metabolic disorders might represent a limit of the studies; indeed, although many pharmacological treatments, producing positive metabolic effects, are also able to modulate autophagic flux and inflammation, it is not clear if the final beneficial effect might occur only by their mechanism of action, rather than because of additionally involved pathways. Finally, although future studies are needed, the observation that anti-obesity and antidiabetic drugs already on the market, including incretin mimetic agents, facilitate autophagy by dampening inflammation, strongly contributes to the idea that autophagy might represent a druggable system for the development of novel pharmacological tools that might represent an attractive strategy for the treatment of obesity and metabolic disorders.

Research advance in autophagy in obesity

Research Progress of Autophagy along with Homeostasis and Tumor

Autophagy and Obesity and Diabetes.

Targeting Autophagy in Obesity: from Pathophysiology to Management.

Research Progress of the Relationship between Autophagy and Lipid Deposition

Targeting Autophagy in the Management of Obesity and Metabolic Diseases

Unmasking the janus faces of autophagy in obesity-associated insulin resistance and cardiac dysfunction.

Regulation of Autophagy in Obesity-Induced Cardiac Dysfunction

Autophagy-regulating miRNAs: potential targets for obesity and related metabolic disorders

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Research progress on the relationship between autophagy and chronic complications of diabetes

Autophagic Regulation of Lipid Homeostasis in Cardiometabolic Syndrome

Role of autophagy in the progression from obesity to diabetes and in the control of energy balance

Advances in the study of autophagy in breast cancer

Research progress of the key targets of autophagy and related drugs in mammalian cells

Progress in the study of autophagy, autophagic cell death and tumor

Advances in the Study of Autophagy and Pulmonary Related Diseases

Autophagy and Mitochondria in Obesity and Type 2 Diabetes

Regulation of adipocyte autophagy — The potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I

Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?

Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases